Geron Corporation (NASDAQ:GERN) reported that the U.S. FDA has granted Fast Track designation to imetelstat for the prospective treatment of adult people with transfusion-dependent anemia following low or Intermediate-1 risk MDS who are non-del and who are resistant or refractory to treatment with an ESA.
Several equities analysts have commented on the stock. Given the stock's recent action, it seemed like a good time to take a closer look at the company's recent data. Zacks Investment Research upgraded Geron Corporation from a "hold" rating to a "buy" rating and set a $2.50 price objective for the company in a research report on Tuesday, October 3rd.
Heading into the stock price potential, Geron Corporation needs to grow just 82.93% to cross its median price target of $3.75. Finally, BidaskClub cut Geron Corporation from a "hold" rating to a "sell" rating in a research note on Saturday, August 5th. The company saw 1.96 million shares trade hands over the course of the day.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $3.75 on the stock, this valuation is based on 2 number of opinions.
The company has mean EPS estimate of -0.04 reported by 1 number of analyst for the quarter ending Current Qtr.(Sep2017).
Geron Corporation (NASDAQ:GERN) as of recent trade, has shown weekly upbeat performance of 0.49% which was maintained at -8.07% in 1-month period.
While having a peek at profitability ratios Geron Corporation (NASDAQ:GERN) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%. The company's forward price to earnings ratio for next fiscal year is 0. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.40 million. The firm's revenue was down 96.8% compared to the same quarter past year. If you are accessing this story on another publication, it was illegally copied and republished in violation of US & global trademark and copyright legislation.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company.
Institutions own 38.80% of Geron Corporation (GERN)'s shares. As of quarter end Aperio Group, LLC had acquired 5,857 shares growing its holdings by 49.3%. The value of the company's investment in Geron Corporation increased from $161,000 to $180,000 a change of 11.8% quarter to quarter. It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Geron Corp. discovers and develops therapeutic products for cancer. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.